Product Details
| Product Name:
JW74 |
CAS No.:
863405-60-1 |
| Purity:
95.00% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | JW74 |
| Description | JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling pathway (IC50: 420 nM). |
| In vitro | Ki-67 expression is reduced from 97.5% in DMSO-treated cells to 86.7% in JW74-treated cells. Relative to DMSO-treated cells, the cellular viability of U2OS cells treated for 72 h treatment with 10 μM JW74 is reduced to 80%. The effect of tankyrase inhibition on cellular viability is tested by performing an MTS assay. Flow cytometry is also performed to determine the expression marker Ki-67 in U2OS following 48 h treatment with DMSO or 10 uM JW74 [2]. JW74 displays a reduction of canonical Wnt signaling in the ST-Luc assay (IC50: 790 nM) [1]. |
| In vivo | The in vivo efficacy of JW74 is evaluated using SW480 cell xenografts, with high doses (150 or 300 mg/kg) administered due to rapid degradation in the organism, as shown by human liver microsome analysis (t1/2=2.5 minutes) and pharmacokinetic analyses (t1/2=30 minutes after peroral injections and t1/2=15 minutes after intravenous injections). JW74 concentrations in tumors range from 4.2 to 72.1 μmol/kg for 150 mg/kg, 1.9 to 11.1 μmol/kg for 300 mg/kg, and reach 2.8 μM in plasma for both doses [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (98.57 mM)
|
| Keywords | Inhibitor | JW74 | JW 74 | inhibit | JW-74 | Wnt |
| Inhibitors Related | Urea | PRI-724 | Wnt pathway activator 1 | L-quebrachitol | MSAB | EMT inhibitor-1 | Wogonin | CHIR-99021 | XAV-939 | Nefopam hydrochloride | KY-05009 | Bisdemethoxycurcumin |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Neuroprotective Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Wnt/Hedgehog/Notch Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1080028-80-3
$88.00 / 1mg
-
CAS:53786-28-0
$29.00 / 10mg
-
CAS:2349372-98-9
$117.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States